INT160852

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.16
First Reported 2005
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 5
Total Number 5
Disease Relevance 5.28
Pain Relevance 0.56

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular region (CD55) plasma membrane (CD55)
CD55 (Homo sapiens)
Pain Link Frequency Relevance Heat
cryotherapy 14 89.28 High High
Inflammation 25 84.80 Quite High
Angina 2 65.12 Quite High
Calcitonin gene-related peptide 1 30.84 Quite Low
metalloproteinase 1 21.32 Low Low
cva 17 5.00 Very Low Very Low Very Low
cytokine 4 5.00 Very Low Very Low Very Low
Inflammatory response 4 5.00 Very Low Very Low Very Low
Pain 4 5.00 Very Low Very Low Very Low
palliative 3 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Cleidocranial Dysplasia 29 100.00 Very High Very High Very High
Metaplasia 2 100.00 Very High Very High Very High
Skin Cancer 8 99.96 Very High Very High Very High
Cancer 30 99.76 Very High Very High Very High
Disease 72 98.32 Very High Very High Very High
Inflammatory Bowel Disease 78 95.88 Very High Very High Very High
Colon Disease 2 87.80 High High
Esophageal Cancer 6 87.00 High High
Paroxysmal Nocturnal Hemoglobinuria 158 86.08 High High
Malignant Neoplastic Disease 19 85.64 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
They act at different levels of the complement cascade (Figure 3): CD55 controls early complement activation, inhibiting C3 and C5 convertases (Burge et al 1981; Medof et al 1984), while CD59 interferes with the terminal effector complement, blocking the incorporation of C9 onto the C5b-C8 complex, forming the membrane attack complex (MAC) (Shin et al 1986; Zalman et al 1986).
Regulation (controls) of CD55
1) Confidence 0.16 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721357 Disease Relevance 0.35 Pain Relevance 0
Complete response for high-grade dysplasia (HGD) (CR-HGD), all dysplasia (CR-D), intestinal metaplasia (CR-IM) and cancer (CR-C) were assessed in patients completing therapy during the study period.
Regulation (response) of CR-D associated with cancer, metaplasia and cleidocranial dysplasia
2) Confidence 0.11 Published 2010 Journal Dis. Esophagus Section Abstract Doc Link 19515183 Disease Relevance 1.67 Pain Relevance 0.26
Complete response for high-grade dysplasia (HGD) (CR-HGD), all dysplasia (CR-D), intestinal metaplasia (CR-IM) and cancer (CR-C) were assessed in patients completing therapy during the study period.
Regulation (response) of CR-IM associated with cancer, metaplasia and cleidocranial dysplasia
3) Confidence 0.11 Published 2010 Journal Dis. Esophagus Section Abstract Doc Link 19515183 Disease Relevance 1.69 Pain Relevance 0.26
The questionnaires (EORTC QLQ-C30, EORTC QLQ-CR38, EQ-5D and EQ-VAS) are filled in by the patients on the day of randomization and on week 4, 12, and 24 after randomization.
Regulation (filled) of EORTC QLQ-CR38
4) Confidence 0.05 Published 2007 Journal BMC Surg Section Body Doc Link PMC1925059 Disease Relevance 0.17 Pain Relevance 0
Eight genes (CYLD, DAF, DKFZp547A023, MUC1, OCLN, PLA2G2A, TIMP1, and ZCCHC4;Table 5) were significantly differentially regulated between normal controls and inflamed DC, and the direction of change was the same as that observed in IBD.
Regulation (regulated) of DAF associated with inflammatory bowel disease and skin cancer
5) Confidence 0.03 Published 2005 Journal PLoS Medicine Section Body Doc Link PMC1188246 Disease Relevance 1.40 Pain Relevance 0.04

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox